Olaparib in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||24/03/2021|
|Rapid review completed||28/04/2021|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib in combination with bevacizumab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||31/05/2021|
|Pre-submission consultation with Applicant||Scheduled|
|Current Status||Pre-submission consultation scheduled|